Network pharmacology of ginsenoside Rg3 in the treatment of ovarian cancer: Mechanism of action and experimental verification.

IF 0.9 4区医学 Q4 PHARMACOLOGY & PHARMACY

International journal of clinical pharmacology and therapeutics Pub Date : 2025-03-21 DOI:10.5414/CP204674

Yibo Zhu, Xizi Lu, Xiaofeng Ding, Lujia Zhu, Guishu Zeng, Boyu Ren, Yi Yun, Xiang Li, Liliang Wei

{"title":"Network pharmacology of ginsenoside Rg3 in the treatment of ovarian cancer: Mechanism of action and experimental verification.","authors":"Yibo Zhu, Xizi Lu, Xiaofeng Ding, Lujia Zhu, Guishu Zeng, Boyu Ren, Yi Yun, Xiang Li, Liliang Wei","doi":"10.5414/CP204674","DOIUrl":null,"url":null,"abstract":"Objective: The aim of this study was to investigate the mechanism of action of ginsenoside Rg3 (Rg3) in the treatment of ovarian cancer (OC).Materials and methods: We used a network pharmacology approach to identify overlapping targets of OC- and Rg3-related genes. The overlapping targets were used for enrichment analysis to construct protein-protein interaction (PPI) networks and identify hub genes. Significantly enriched pathways were validated using in vitro experiments.Results: After identifying the relevant targets of OC and Rg3, 53 overlapping targets were identified. Enrichment analysis revealed that the PI3K-Akt, Ras, Rap1 pathways were significantly enriched. Ten hub genes (AKT1, MMP9, STAT3, JUN, MMP2, EGFR, FGF2, PPARG, KDR, and HSP90AA1) were identified in the PPI network. In vitro experiments revealed that Rg3 exerted therapeutic effects by promoting the apoptosis of OC cells and inhibiting the PI3K-Akt signaling pathway.Conclusion: The combination of network pharmacology and in vitro experimental validation revealed that Rg3 may play a therapeutic role in the treatment of OC by promoting the apoptosis of OC cells via the inhibition of the PI3K-Akt signaling pathway. This provides a new idea for the clinical application of Rg3 in the treatment of OC.","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of clinical pharmacology and therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5414/CP204674","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The aim of this study was to investigate the mechanism of action of ginsenoside Rg3 (Rg3) in the treatment of ovarian cancer (OC).

Materials and methods: We used a network pharmacology approach to identify overlapping targets of OC- and Rg3-related genes. The overlapping targets were used for enrichment analysis to construct protein-protein interaction (PPI) networks and identify hub genes. Significantly enriched pathways were validated using in vitro experiments.

Results: After identifying the relevant targets of OC and Rg3, 53 overlapping targets were identified. Enrichment analysis revealed that the PI3K-Akt, Ras, Rap1 pathways were significantly enriched. Ten hub genes (AKT1, MMP9, STAT3, JUN, MMP2, EGFR, FGF2, PPARG, KDR, and HSP90AA1) were identified in the PPI network. In vitro experiments revealed that Rg3 exerted therapeutic effects by promoting the apoptosis of OC cells and inhibiting the PI3K-Akt signaling pathway.

Conclusion: The combination of network pharmacology and in vitro experimental validation revealed that Rg3 may play a therapeutic role in the treatment of OC by promoting the apoptosis of OC cells via the inhibition of the PI3K-Akt signaling pathway. This provides a new idea for the clinical application of Rg3 in the treatment of OC.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of clinical pharmacology and therapeutics 医学-药学

CiteScore

1.70

自引率

12.50%

发文量

116

审稿时长

4-8 weeks

期刊介绍： The International Journal of Clinical Pharmacology and Therapeutics appears monthly and publishes manuscripts containing original material with emphasis on the following topics: Clinical trials, Pharmacoepidemiology - Pharmacovigilance, Pharmacodynamics, Drug disposition and Pharmacokinetics, Quality assurance, Pharmacogenetics, Biotechnological drugs such as cytokines and recombinant antibiotics. Case reports on adverse reactions are also of interest.